Background: The U.S. Office for Human Research Protections has proposed that end points of randomized trials comparing the effectiveness of standard medical practices are risks of research that would require disclosure and written informed consent, but data are lacking on the views of potential participants.
T
he emergence of studies conducted in health care settings that blur the distinction between research and clinical practice has fanned a debate (1-5) that began in March 2013 when the U.S. Office for Human Research Protections (OHRP) criticized a study (6) comparing target oxygen saturation levels in premature infants (7) . The debate revolves around the types of risks that should be attributed to research that compares 2 or more commonly used clinical practices by randomly assigning participants between them. On 24 October 2014, the OHRP announced draft guidance clarifying that, for studies that compare treatments and randomly assign patients, the risks of the treatments should be considered risks of research and disclosed as such (8) . But many large ongoing studies of this type, such as those conducted by the National Institutes of Health Collaboratory (9), have not required such disclosures; indeed documented informed consent for such studies may be prohibitively difficult or logistically impossible. According to OHRP, however, in observational studies that compare 2 treatments chosen by clinicians and their patients, the risks of treatment are not considered to be risks of research and thus are not currently required to be disclosed in the informed consent process (6, 10) .
Research on medical practices (ROMP) poses challenges for the protection of human subjects and informed consent. For such research, which is typically conducted in the context of patients receiving care from their physicians, the assessment of risk and approach to informed consent can differ from research that tests new interventions or that is conducted by researchers not providing care to the patient participants (11) (12) (13) (14) . Current regulations in the United States instruct institutional review boards (IRBs) to "consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research)" (10) . Further, the current regulatory framework uses risk categorization to drive specific approaches to informed consent (15, 16) . For example, the ability to alter or waive informed consent is only possible for research that "involves no more than minimal risk to the subjects" (17) . But the draft guidance defines the risks associated with the standard treatments being evaluated as risks of research if "a standard of care that at least some of the individual subjects will be assigned to receive will be different from the standard of care that they would have received if they were not participating in the study;" further, the guidance requires that these risks must be disclosed to par- 
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IMPROVING PATIENT CARE ticipants (8) . The draft guidance is intended to assist institutional review boards in interpreting federal regulations. It may, however, run counter to the ethical principle of respect for persons underlying the regulations to the extent that it takes a narrow view of participant preferences, values, and concerns about research, especially with how participants weigh benefits of research relative to perceived risks (15) .
Framing the guidance more appropriately is difficult given the absence of data about the views of potential participants. Empirical data can contribute to normative and policy deliberations by examination of how the public considers the risks of randomization and how the public makes tradeoffs between preferences for notification or permission to participate and the ability of researchers to conduct ROMP. We therefore conducted a survey among a sample of U.S. adults to assess these issues in the context of hypothetical research scenarios involving observational or randomized studies of standard medical practices.
METHODS

Overview
We conducted a Web-based survey to assess attitudes about ROMP in August 2014. To explain key features of ROMP, we developed 3 narrative videos that were embedded in the survey. We developed the survey questionnaire and pilot-tested the videos using focus groups. This study was approved by the University of Washington and Stanford University Institutional Review Boards.
Sample Selection
Our sample was obtained from Research Now and derived from members of an online research panel and a "river" (convenience) sample of Internet users invited to participate when visiting general, social media, and loyalty Web sites. Panel members received a small incentive by a points-based reward program, and their identity was validated by detection of a unique computer ID. Multiple survey completions were avoided by use of a unique URL for each survey. Quota sampling was used to ensure inclusion of key population subgroups by geography (Northeast, Midwest, South, and West), gender, age, race, and ethnicity.
Development of Narrative Videos
Because this type of research is not familiar to most people, we created 3 animated narrative videos (with Alex Thomas, MD, and health communication specialist Gary Ashwal, both of Booster Shot Media), each 2 to 3 minutes long, that focused on the variability in use of approved antihypertension medications and research to learn which treatments are better. With Booster Shot Media, the research team identified key concepts about ROMP that distinguish it from other clinical research and were addressed in the survey. On the basis of these concepts, Booster Shot Media developed storyboards, scripts, and draft videos, each of which was revised in collaboration with the research team. We showed the videos as part of the focus groups and solicited feedback to inform revisions for clarity (for example, we slowed the narration in response to comments that it was too fast) and overcome common misconceptions (for example, that medical research only compares treatments with placebo, rather than with each other). The first video explains factors that influence variation in clinical practice, the second explains randomization and medical record review, and the third explains 3 approaches to notifying patients about research and obtaining their permission to participate. We used conventional terms for notification ("general information"), oral permission ("verbal permission"), and written consent ("written agreement"). We described the spectrum of medical record review and randomization comparing usual treatments as "research on medical practices" because such terms as "learning health systems," "comparative effectiveness research," and "pragmatic trials" are not commonly used by the public. We believed that "research on medical practices" was more descriptive, and this was confirmed in our focus groups.
Survey Development and Administration
To develop the survey, we conducted 8 focus groups of 4 to 7 participants each and 2 small-group interviews of 2 to 3 participants each; participants were recruited from clinics at 3 health care institutions. We revised the survey on the basis of review by expert consultants and through 13 cognitive interviews of participants derived from the focus group sampling frame and patrons of a public library by using the "think aloud" technique (18) .
The survey began with questions about attitudes toward research, physicians, and health systems, inter-
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Attitudes Toward Risk and Informed Consent for ROMP ORIGINAL RESEARCH spersed with the 3 videos and questions to assess understanding of ROMP concepts. The second section asked questions about preferences for notification and permission to enroll in ROMP, perceptions of risk, and willingness to participate in ROMP in the context of 3 scenarios. The first scenario described a medical record review comparing the outcomes of 3 medications in patients newly diagnosed with hypertension, with the medications being described as approved by the U.S. Food and Drug Administration and prescribed on the basis of physician judgment and patient preferences. The second scenario described a variant of the first scenario in which patients were randomly assigned to one of these medications, in an unblinded manner, with usual clinical follow-up. The scenario stated that "the doctor will not change the [assigned] medication unless the doctor or patient has concerns." The third scenario described a similar randomized study comparing 3 medications for "a more serious condition that increases your risk for stroke." The last section of the survey consisted of questions about demographic characteristics and experience with health care for serious illness and clinical research. The videos (19 -21) and the survey instrument (22) Table 1 (available at www.annals.org). Participants from the research panel and river sample were invited to take the survey and were sent a single e-mail that contained a link to the survey Web site.
Statistical Analysis
Sample characteristics are shown in Table 1 alongside data from the U.S. Census Bureau (23) and the Centers for Disease Control and Prevention National Health Interview Survey (24). The survey required a response to all items, although the respondents were given the option of "prefer not to answer" for the questions about household income and education. Estimates of sampling error could not be calculated because both samples consisted of volunteers only; therefore, the probabilities of selection and thus response rates cannot be calculated because the sampling frame is unknown (25) .
Role of the Funding Source
The study was funded by the National Center for Advancing Translational Sciences at the National Institutes of Health. The funding source did not participate in the design, conduct, or analysis of the study or in the decision to submit the manuscript for publication.
RESULTS
Respondent Characteristics
Demographic characteristics of survey respondents are shown in Table 1 and Appendix Table 2 (available at www.annals.org). Of the 1095 completed survey responses we received, 805 were from the panel and 290 were from the river sample. Results are reported for the combined group of respondents from the panel and river samples, with no weighting or adjustments applied. We report the response metrics currently recommended for online surveys (25, 26) . The completion rate representing all respondents who attempted to complete a survey even if they were screened out was 41.6% (1335 of 3208 respondents) for the panel survey and 90.1% (472 of 524 respondents) for the river survey. The study-specific eligibility rate is equivalent to Response Rate 6 as defined by the American Association for Public Opinion Research for a study-specific sample (27 
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Demographic characteristics (geography, gender, age, race, and ethnicity) of respondents differed from those reported in the 2013 U.S. Census data (23) in that our sample had a lower proportion of Asian Americans, fewer respondents in the 21-to 26-year age group but more in the 27-to 44-year age group, and respondents with higher average educational level and household income (23) . Self-reported health status was somewhat poorer in our sample relative to the national average, with smaller percentages of our sample reporting excellent or very good health (24); 95.4% and 85.0% of respondents trusted their physicians and health systems, respectively, to put their well-being above all other considerations (Appendix Table 1 ). Respondents correctly answered a mean of 5.04 of the 6 questions about understanding of ROMP (84%) (Appendix Table  1 ). The percentage of respondents answering all 6 questions correctly ranged from 76.5% to 95.3%.
Support for ROMP
Respondents showed strong support for research to determine which standard treatments are best; 97% agreed (74.3% strongly) that health systems should conduct this type of research ( Table 2) , and 92.8% indicated that it was always (15.3%), usually (46.4%), or sometimes (31.1%) acceptable for health systems to use randomization to compare how well standard treatments work. However, 75.4% had not participated in a randomized clinical study (Appendix Table 1 ).
Preferences for Notification or Permission to Participate in ROMP
Most respondents preferred to have a discussion with their provider followed by either written or oral permission to participate in each of the 3 ROMP scenarios ( Table 3 ). The proportions of respondents who indicated a preference for written permission for each of the 3 scenarios were similar: 51.0% for the medical record review scenario, 47.2% for the hypertension scenario, and 52.4% for the more serious condition scenario. The proportions of respondents who indicated a preference for written permission for the randomized scenario of the more serious condition (52.4%) and the medical record review (51.0%) or randomized hypertension (47.2%) scenarios were similar.
To assess these preferences relative to the ability to conduct research among respondents who initially indicated a preference for either discussion plus oral or written permission, we further measured their preferences if getting permission in one form or the other "would make this research too difficult to carry out." One of the response options provided was, "I would prefer that the research not be conducted" ( Table 4) . For all 3 scenarios, most preferred a less demanding approach rather than the research not being conducted. Most respondents who preferred written or oral permission for each of the 3 scenarios still supported doing research if permission was too difficult to obtain, although more indicated a preference that research not be conducted for the randomized study of the more serious condition (37.2%) or hypertension (31.8%) than research using medical records (26.8%) ( Table 5) .
Of participants surveyed, 84.5% preferred that they be asked permission to participate in the medical records review study by their physician as opposed to by a researcher or research nurse not involved in their care, whereas 85.2% preferred their physician in the hypertension scenario and 86.8% in the more serious condition scenario (see survey questions 12, 21, and 35 in Appendix Table 1 ).
Perceptions of Risk and Willingness to Participate in ROMP
In general, most respondents perceived "a little" more risk with each scenario than with "just having their doctor prescribe the medications" ( Table 6) . A higher percentage perceived the risks of ROMP to be "a lot" more with randomization for hypertension or a serious condition than for medical record review, and a higher percentage perceived no additional risk from research using medical record review than from randomized studies. In addition, whereas most respondents were willing to participate in all 3 scenarios, more indicated a willingness to participate in the medical record review Attitudes Toward Risk and Informed Consent for ROMP ORIGINAL RESEARCH scenario than the randomized studies for hypertension or a more serious condition ( Table 6) .
DISCUSSION
Almost all respondents to our survey supported ROMP, including the use of randomization, and were willing to participate in such research. Most, however, wanted to be asked for their permission to participate. Of note, the percentage preferring written permission for research using medical records was almost as high as that for scenarios involving randomization. This suggests that persons want to be asked for permission to participate in such research regardless of whether it affects treatment decisions. These findings are consistent with other studies that reveal broad support for, and willingness to participate in, research (27) but also a strong desire to be asked for permission before research using medical records (28) , biospecimens (29, 30) , or cluster randomization (31) . These data also suggest that, unlike the OHRP's interpretation of the federal regulations, the public does not base disclosure preferences about research solely on whether the research plan determines treatment assignment. In addition, the expressed preference for permission to be obtained by physicians rather than researchers not involved in care seems contrary to the regulatory requirement that "investigators" obtain informed consent (32) .
Given the widespread preference among our sample for being asked permission to participate in both randomized and nonrandomized ROMP, we were surprised to find that, when asked to choose between less demanding approaches to consent or precluding research from being done, most respondents were willing to accept less demanding approaches. Fewer even preferred notification through the receipt of general information, without expressed permission, over not allowing the research to proceed. This suggests that preferences are contextual or contingent on certain conditions being met; although persons value both research and the ability to agree to or decline participation in studies, such as those described in our scenarios, many prioritize the former over the latter. Thus, in cases in which conducting research with particular informed consent requirements may be impractical, such as written documentation, most respondents preferred that the research go forward.
The finding that most respondents thought there was at least a little more risk from research than usual clinical care, even when the research involves only medical record review, suggests that persons do perceive research-specific risks in ROMP. Of note, there was only a small difference between the proportion of respondents who felt that medical record review posed "a little more risk" than usual care and the proportion who felt that way about the randomization scenarios. This suggests that a substantial portion of respondents do not regard the possibility of being randomly assigned to a treatment different from what they would otherwise have received as the source of the perceived risk. Again, this perception of risk from research involving only the review of medical records contrasts with the OHRP guidance, which does not consider the risks associated with standard care in an observational study to be risks of research (6). But we do not know the nature of the risks that respondents might have envisioned as they considered the 3 scenarios. 
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Our study has some limitations. First, our survey asked about hypothetical scenarios, so notification and permission preferences and willingness to participate in actual situations may differ. Second, we cannot assess the effects of nonresponse bias due to our sampling method. We chose our sampling method to obtain an overall sample with diversity in geography, age, gender, race, and ethnicity. But our sample differed somewhat from the general U.S. population in terms of race, age, income, education, and self-reported health status. Although we do not know how our sample compares with potential participants in ROMP, at least 1 population-based study found that poor health and some college-level or higher education were predictors of participation in clinical trials in general (33), suggesting that our sample may be similar to persons likely to participate in ROMP.
Our findings suggest strong support for research that compares usual clinical practices to determine the best ways of treating a particular condition and willingness to participate in such research. Respondents also favored being asked for permission to participate in this research, regardless of whether it affects treatment decisions; thus, our results indicate that respondents might not attribute and categorize risks in the same way as the federal regulatory draft guidance. These findings may indicate, on one hand, that federal regulations do not go far enough to ensure that research participants are informed about and asked for permission to participate in observational research, including studies of deidentified data that are currently not considered human subjects research. If requiring written permission would preclude the conduct of research, however, most persons would rather accept less elaborate notification or approaches to consent than see the research not be done; they thus seem willing to make tradeoffs between imposing full consent requirements and allowing research to proceed.
If the proposed OHRP guidance is adopted, it would define potential differences in outcome as risks of research, and therefore randomized comparative effectiveness research will nearly always need to be classified as greater-than-minimal risk. Thus, the OHRP proposal seems to rule out options that many potential research participants would want to have available, such as a waiver of documentation or a waiver or alteration of consent. Although the OHRP approach could address the concerns of a consent-requiring minority, it may do so at the expense of a research-supporting majority. Fulfilling the ethical principle of respect for persons in the conduct of ROMP requires finding the appropriate balance between the concerns of participants (which may be broader than current regulatory definitions of risk) and an appreciation of the public's desire for research to be conducted. 
